SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Traders are linking Quants sharp rally to reports of a Clearing House banking initiative involving Quant, alongside its role in financial-system interoperability; the tokens limited supply is fueling a scarcity and institutional-adoption narrative. Bullish momentum dominates, but some traders warn of a sharp pullback and question how much the banking use case would directly benefit QNT.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEARs sharp rally and move to a one-year high are being linked by traders to Bitwises spot-ETF filing and planned listing, with institutional-access optimism fueling bullish discussion. Some expect the momentum to continue, while others warn of a pullback or sell-the-news reaction.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Attention centers on the upcoming Phase 3 EMT-2 cancer-trial results and uncertainty around Amarins LR-EtEPA patent claims, with traders debating whether either could strengthen the companys strategic value. Reports of failed cardiovascular-outcome trials at other drugmakers are also fueling speculative buyout talk, while skeptics point to the unresolved patent questions and weak share performance.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

FETs recent rebound and breakout have drawn attention amid renewed interest in AI-focused crypto tokens, with traders pointing to Fetch.ais AI-agent ecosystem and product developments as potential support for the narrative. The reaction is mostly bullish, though some question whether the move can continue, noting resistance and the broader crypto markets influence.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Attention centers on Aerodromes planned merger with Velodrome and expansion into a unified cross-chain liquidity protocol, including Ethereum mainnet, alongside upgrades to liquidity allocation and token buybacks. Many traders see the rollout and broader Base activity as potential growth drivers, while others remain cautious about execution delays, token emissions, and whether the optimism will translate into sustained price gains.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

CROs price swings have reignited debate over its large token supply and the return of previously burned tokens, which many traders see as persistent dilution and a drag on performance. Some are encouraged by brief rebounds and Crypto.com developments, while skeptics expect gains to fade amid continued selling pressure.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

Much of the discussion speculates that AbbVie could acquire SELLASs AML assets, with traders pointing to AbbVies oncology business and venetoclax franchise as a possible strategic fit; no bid is confirmed, and the REGAL Phase 3 results remain pending. AbbVies agreed Apogee acquisition and its recent strength alongside other healthcare stocks also feature in the conversation.

PolySwarm

A burst of trading volume and a modest price move have traders watching NCT for a possible breakout, with some pointing to heavy South Korean trading and past rallies as reasons for optimism. Others see the activity as another speculative pump and question whether it can hold.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS is drawing attention for a technical rebound after an eight-session losing streak, with traders describing the shares as oversold and pointing to bullish chart patterns. Bullish comments also cite the companys strong Q2 results and raised 2026 outlook, while some investors remain cautious about whether the rebound can hold.

Quantinuum Inc. is a quantum computing platform that offers solutions like hardware platforms, developer tools, application libraries and solution-targeted intellectual property (“IP”). The company was founded on January 20, 2026 and is headquartered in Broomfield, CO.

Quantinuum Inc. - Ordinary Shares - Class A

Quantinuum Inc.

Quantinuums finalized $100 million CHIPS R&D award is drawing attention as traders view federal backing as validation of its quantum-computing plans. Reactions are mixed, with some welcoming the support while others question the companys valuation and volatile trading.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
